GELF high-tumor-burden criteria (follicular lymphoma)
GELF high-tumor-burden criteria (follicular lymphoma) - a deterministic tool in Sophie Well's Clinical Scoring & Risk group.
Open the GELF high-tumor-burden criteria (follicular lymphoma) → Runs in your browser. No signup, no tracking.
What this is
GELF high-tumor-burden criteria (follicular lymphoma) is one of 230 deterministic tools in Sophie Well's Clinical Scoring & Risk group. GELF high-tumor-burden criteria (follicular lymphoma) - a deterministic tool in Sophie Well's Clinical Scoring & Risk group.
When to use it
Use this tool when you need a quick, citable reference. Every calculation runs entirely in your browser - no inputs leave your device, no account is required, no AI is involved. The site enforces a strict Content Security Policy and ships no analytics or third-party CDN.
References
Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires (GELF). J Clin Oncol. 1997;15(3):1110-1117. Read the source ↗
Worked example: GELF high-tumor-burden criteria MET (1 criterion: mass > 7 cm) -- treatment is indicated rather than observation.
Sophie Well is a reference and educational tool. Not medical, legal, or financial advice. Does not replace clinician judgment, professional billing review, or legal counsel.